Trial Profile
A retrospective evaluation of icotinib for safety and efficacy in Chinese patients with advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2015 New trial record